

# **Research and Continuous Improvement Committee Meeting Minutes & Chat**

**Location:** Microsoft Teams

**Date:** 7/10/26

**Time:** 9:00AM

**Organizers:** Jonathan Mouchet, DOH; Cyrus Rautman, DOH; Katy Freytag, DOH; Dominick Zurlo, DOH; Brenda Martinez, DOH; Jorge Gonzales, DOH; Leslie Peterson, DOH; Adrian Estrada, DOH; Cathy Augeri, DOH; Dan Jennings; Vicente Roybal, DOH; Robert Truckner, DOH; Raymond Gallegos, DOH

**Attendees:** Brenda Burgard, Chris Peskuski, Roman Palitsky, JoEllen Schimmels, Don Moser, Skye Rivers SFR, Gregory Evans, James Brown, Kate Hawke, Danielle Leonard, Jeff Steinborn, Hana Rose, Hanifa Nayo Washington, Jason Brooks, Danielle Leonard, Reuben Sutter, Hana Rose, Jeff Steinborn, Skye Rivers SFR, Catherine Sanchez Catherine Sanchez, Ellen Schimmels, Lida Fatemi, Denali Wilson, Anne-Marie M Cooper, James Ferreira, Eric Barlow, Deb Thorne, Catherine Warnock, Michael Williams, Jim Dodson

**Minutes Taker:** Cyrus Rautman, DOH

***\*This meeting was recorded. For specific details pertaining to the meeting, please refer to the recording located on the Medical Psilocybin Advisory Board Website: [Psilocybin Advisory Board](#)***

## **Agenda items**

### **1. Announcements & Introductions**

Dominick opened the meeting to the public at 9:01 and introduced Dan Jennings. Dan introduced the committee, went over the agenda, and then allowed Dominick to introduce department staff and committee attendees to introduce themselves.

- Skye Rivers, Santa Fe Reporter
- James Brown, PharmD
- Don Moser, Las Vegas, NM, community member
- Danielle Leonard, LMHC, NMHU
- Hana Rose, BSW student in Silver City, curandera
- Brenda Burgard, chair, TAE committee

- Gregory Evans, Ignite Synergy
- Kate Hawke, trauma therapist, MAPS member
- Chris Peskuski, chair, propagation committee
- Hanifa Nayo, PMHA
- Ellen Schimmels, mental health NP
- Jeff Steinborn, state senator, lead author of SB219
- Roman Palitsky, psychologist, Emory University, guest presenter

Dan then reminded committee attendees of the committee meeting norms and process, then introduced the guest speaker.

## **2. Guest Presentation: Dr. Roman Palitsky**

Dr. Roman Palitsky, Director of Research Projects in Spiritual Health at Emory University School of Medicine

Risk reduction, safety monitoring and adverse experiences in psychedelic therapy

Adverse event: any abnormal sign, symptom or disease temporally associated with the subject's participation in research, whether or not considered related to the subject's participation in the research

Serious adverse events (SAEs) reported at low rates: 8-10% in recent research studies

- Adverse event (specific to dosing period, may or may not have negative impact)
- Adverse effect (occurs in days, weeks, months after dosing, typically involves negative impact)

Dr. Palitsky presented on his research on adverse event measurement and reporting, and possible future research options, as well as how these ideas can be applied to the New Mexico program and how NM can participate in this research moving forward.

## **3. Intersessional Workgroup Report-Outs**

Dan then introduced the three intersessional workgroups and allowed them opportunities to report on the work they've done in developing frameworks for harm reduction and quality improvement in their respective domains.

Harm-reduction/QI Framework Consensus:

Workgroup 1: Care Pathway and Safety

Workgroup 2: Participant Experience and Fit

Workgroup 3: Data and Reporting Architecture

## **4. Next Meeting Date Announcement & Public Comment**

Dan announced the next meeting would be August 7, during which the intersessional workgroups would report out their work toward developing a Core/Extended Dataset Framework Consensus. He then opened the meeting to public comment.

Dominick answered a question about the department's AI policy with regards to data analysis by explaining that the policy is fairly restrictive for data safety and privacy reasons but that the issue can be revisited in the future. The meeting was then adjourned at 10:55.

## **Chat**

---

### **Medical Psilocybin - Research and Continuous Improvement Committee 7/10/26**

#### **External**

Mouchet, Jonathan, DOH started recording.

**Gonzales, Jorge, DOH**

**9:02 AM**

Reminder:

This meeting is being recorded

Please remember to keep language appropriate as the recordings are made public on the Advisory Board Website

**Gonzales, Jorge, DOH**

**9:04 AM**

How to raise your hand to speak:

- If on a computer – click on the “hand” icon near the top of the Teams window (it says “Raise” under the icon)
- If on the Teams app on a phone, please press the ellipses (three dots) in the menu and then the “hand” icon will appear, and you can select it
- If you are joining through voice only on a phone, press \*5 to raise or lower your hand

How to Unmute:

- Once your name is called, you will be able to unmute:
- To unmute/mute on Teams on a Computer or on the Teams Phone App click on the microphone icon:
- On a computer it is in the upper right area of the Teams window.
- On a phone it is usually in the lower left of the Teams App, however, different models of phone (Apple, Android, etc...) may have the mute/unmute icon in a different location:

- Telephone: voice only - press \*6 to unmute/mute

**Kate Hawke**

9:06 AM

Intro: Kate Hawke from Santa Fe. 40 year MAPS member, trauma therapist, harm reduction, currently researching psychedelics and end of life care.

**Chris Peskuski**

9:07 AM

Chris Peskuski advisory board member, veteran and community advocate

**Hanifa**

9:08 AM

Hanifa Nayo- Santa Fe PMHA ALLIANCE

**Ellen Schimmels**

9:08 AM

Ellen Schimmels psych mental health nurse practitioner from Albuquerque

**Danielle Leonard LMHC**

9:08 AM

Cant seem to open the mic

**Danielle Leonard LMHC**

9:10 AM

Hi, I am Danielle Leoanrd I am a psychotherapist living in Santa Fe and research peak and mystical expereinces with NMHU. I am on work group 2 and 3 for RACI.

**Gonzales, Jorge, DOH**

9:11 AM

If you have been unmuted and your microphone still seems not to be working - one issue some individuals have is their microphone not being connected to the computer at the moment (it seems to especially happen with headsets), so you may need to ensure your microphone is active and connected to your computer.

**Palitsky, Roman**

9:12 AM

Hi I'm Roman Palitsky, licensed psychologist and faculty at Emory University, I'm honored to be a guest presenter for today's meeting.

**Brown, James**

9:15 AM

So excited to have you here today!!

**Gregory Evans**

9:42 AM

Here is a link for the Peterson piece:

[A Theological Reckoning with 'Bad Trips'](#)

**Kate Hawke**

**9:48 AM**

Thanks for this enlightening presentation!

**Palitsky, Roman**

**9:49 AM**

[roman.palitsky@emory.edu](mailto:roman.palitsky@emory.edu)

**Danielle Leonard LMHC**

**9:49 AM**

On that last slide - Is there a scoring or coding structure that supports monitoring trends over time, and have you thought about what a program-level dashboard or periodic review of AE data might look like? I'm working on how our program would monitor these findings on an ongoing basis, not just case by case.

**Palitsky, Roman**

**9:52 AM**

i'm also happy to address unanswered questions via email

**Danielle Leonard LMHC**

**9:56 AM**

I'd like to pick up on Rob's question about patients who see this as their last hope and then don't respond. Roman, your treatment-confidence item means we can now detect that worsening - which raises the "then what" question. Once we can see it, what happens next? Both clinically for that individual, and at the program level - feeding back into how we set expectations, frame consent, and prepare patients.

**Hanifa**

**10:15 AM**

Asking what supports do you have or desire to have post treatments is so important

**Palitsky, Roman**

**10:16 AM**

happy to stick around, and thank you so much for having me here

**Chris Peskuski**

**10:16 AM**

Thank you so much

**Zurlo, Dominick, DOH**

**10:16 AM**

thank you!

**Kate Hawke**

**10:18 AM**

I'm wondering how the intersession workgroups get set up. I don't need to get on EVERYTHING LoL but would like to understand the process.

**Gregory Evans**

**10:19 AM**

Kate Hawke 7/10/2026 10:18 AM

I'm wondering how the intersession workgroups get set up. I don't need to get on EVERYTHING LoL but would like to understand the process.

Careful what you ask for friend...

**Danielle Leonard LMHC**

**10:19 AM**

James?

**Danielle Leonard LMHC**

**10:28 AM**

I am thinking that the piece we haven't yet worked on in harm reduction is the feedback loop. Whether we use OPEN or another system, our framework covers what gets collected, from whom, and when -but not the response mechanism. When the data surfaces something, what is the program's responsibility for responding, who reviews findings and on what timeline, and what does the program own in terms of making change - adapting consent, preparation, training, or protocols based on what we learn? I'd like to think about sketching that half of the loop. Worth naming that this piece touches budget -staff time for review, clinical capacity to respond, system costs - and involves facilitators and clinical staff early since they'll live with it. How do we scope it deliberately rather than assume it rides on existing workload.

**Brown, James**

**10:36 AM**

Next work group meeting focus points:

Outcome Monitoring- Feedback loop research, data points, process, ideas, feedback, quality, aggregation of everything, improvement, others cores needed

**Danielle Leonard LMHC**

**10:38 AM**

[daniellelouiseleonard@gmail.com](mailto:daniellelouiseleonard@gmail.com)

**Brown, James**

**10:38 AM**

Kate. We would love to have you on the team

**Palitsky, Roman**

**10:38 AM**

I am thinking that the piece we haven't yet worked on in harm reduction is the feedback loop. Whether we use OPEN or another system, our framework covers what gets collected, from whom, and when -but  
Something that some groups have done with the PAT-AE has been to identify a subset of criteria that are "fact-finding" and another (much smaller) subset that are clear targets for response, with a specific plan to respond to those more restricted criteria when they occur

**Hanifa**

**10:42 AM**

What is the feedback loop on data collected back to public, research, etc., constituents?

**Kate Hawke**

**10:42 AM**

Kate. We would love to have you on the team  
Thanks, the workgroups are already doing a great job and I'm happy to have you continue without me. But let me know if there's a particular way I might help.

**Brown, James**

**10:45 AM**

Dominic is there anyway to get a list of those already determined data points?  
Thank you Dan for always being an amazing RACI Chair!!

**Chris Peskuski**

**10:48 AM**

Thanks Dan and everyone else. I've got to go. Appreciate you all.

**Danielle Leonard LMHC**

**10:49 AM**

It helps. thank you dan

**Gonzales, Jorge, DOH**

**10:53 AM**

How to submit written public comments:

- Please send written public comment to the program email at:  
[medical.psilocybin@doh.nm.gov](mailto:medical.psilocybin@doh.nm.gov) and include the committee's name in the subject line.
- If referencing documents from other sources/websites:
  - Do not include the document, only a working - accessible hyperlink;
  - Documents must be sent with context provided (i.e. do not simply send a research article);
- The comment must relate to the topics discussed in the meeting.

- Documents are limited to no more than 3 pages (letter size) in length and must be in 10-point font or larger.
- Please remember to include your full, legal name and any organizational affiliations you may be representing (if any) on the documents.
- To be included, please send your comment by 5:00 PM the business day after the meeting.

**Don Moser**

**10:54 AM**

Unknown User 7/10/2026 9:52 AM

i'm also happy to address unanswered questions via email 😊

Appreciate the discussion on adverse events as well as the beneficial ones.

**Mouchet, Jonathan, DOH stopped recording.**